According to The Washington Post (WP), a recent public records request has revealed that drug companies purchased special access onto these panels, where they were given the keys to the kingdom in swaying decision-makers about official drug policy.

Based on critical information gathered from hundreds of leaked emails, pharmaceutical companies have doled out hundreds of thousands of dollars over the years to attend private meetings with the FDA, many of which were geared towards the regulation and approval of painkiller drugs.